Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Resolutions from the Annual General Meeting 2023 in Pharmacolog i Uppsala

Perpetua Medical
Download the release

The English translation of the resolutions is an unofficial translation of the Swedish original. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

The shareholders of Pharmacolog i Uppsala AB (publ) held the Annual General Meeting on June 30, 2023 in Uppsala.

Annual report and results
The annual report and auditor's report were presented and the income statement and balance sheet were adopted. It was decided to dispose of the company's earnings in accordance with the Board's proposal.

Discharge from liability
The Annual General Meeting resolved to discharge the members of the Board of Directors and the CEO from liability.

Fees
The Board fee was set at SEK 150,000 to the Chairman and SEK 100,000 each to the other Board members. Remuneration to the company's auditor was resolved to be paid in accordance with current accounts.

Board
The Annual General Meeting resolved to re-elect Erik Hedlund and Ragnar Linder and to elect Anders Hedlund and Henrik Magnusson Hjorth as new members. Erik Hedlund was also re-elected as Chairman of the Board.

Auditor and deputy auditor
The Annual General Meeting resolved to re-elect Folkesson Råd & Revision AB as auditor until the end of the next Annual General Meeting with approved auditor Sten Eriksson as auditor in charge.

Issue authorizations
The Annual General Meeting resolved to authorize the Board of Directors, on one or more occasions, for the period until the next Annual General Meeting, to resolve to increase the company's share capital up to the limit for share capital according to the Articles of Association that exists the first time the issue authorization is exercised. The authorization may be used to issue shares, warrants and/or convertibles. If the Board of Directors exercises the authorization, it may also be done with deviation from the shareholders' preferential rights and/or with provisions for non-cash issue or set-off.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.